SEARCH

SEARCH BY CITATION

References

  • 1
    Bleyer A,Viny A,Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist 2006; 11: 590601.
  • 2
    Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR). Cancer in Australia 2001. AIHW cat. no. CAN 23 (Cancer Series no. 28), 2004.
  • 3
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 4
    Boissel N,Auclerc MF,Lheritier V,Perel Y,Thomas X,Leblanc T,Rousselot P,Cayuela JM,Gabert J,Fegueux N,Piguet C,Huguet-Rigal F, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 77480.
  • 5
    Grier HE,Krailo MD,Tarbell NJ,Link MP,Fryer CJ,Pritchard DJ,Gebhardt MC,Dickman PS,Perlman EJ,Meyers PA,Donaldson SS,Moore S, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694701.
  • 6
    Mitchell AE,Scarcella DL,Rigutto GL,Thursfield VJ,Giles GG,Sexton M,Ashley DM. Cancer in adolescents and young adults: treatment and outcome in Victoria. Med J Aust 2004; 180: 5962.
  • 7
    Bleyer A,Montello M,Budd T,Saxman S. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer 2005; 103: 18917.
  • 8
    Bleyer A,Budd T,Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 2006; 107(7 Suppl ): 164555.
  • 9
    Greenberg HS,Chamberlain MC,Glantz MJ,Wang S. Adult medulloblastoma: multiagent chemotherapy. Neuro Oncol 2001; 3: 2934.
  • 10
    Carrie C,Lasset C,Blay JY,Negrier S,Bouffet E,Barbet N,Montbarbon X,Wagner JP,Lapras C,Deruty R. Medulloblastoma in adults: survival and prognostic factors. Radiother Oncol 1993; 29: 3017.
  • 11
    Sonnichsen DS,Hurwitz CA,Pratt CB,Shuster JJ,Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 5328.
  • 12
    Smith SD,Rosen D,Trueworthy RC,Lowman JT. A reliable method for evaluating drug compliance in children with cancer. Cancer 1979; 43: 16973.
  • 13
    Richardson JL,Shelton DR,Krailo M,Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990; 8: 35664.
  • 14
    Bleyer A,Barr R,Hayes-Lattin B,Thomas D,Ellis C,Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008; 8: 28898.
  • 15
    National Cancer Statistics Clearing House, Australian Institute of Health and Welfare Canberra, Australia. Available from: http://www.aihw.gov.au/cancer/ncsch/index.cfm.
  • 16
    Smeland S,Wiebe T,Bohling T,Brosjo O,Jonsson K,Alvegard TA. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 2004; 75: 928.
  • 17
    Ferrari S,Smeland S,Mercuri M,Bertoni F,Longhi A,Ruggieri P,Alvegard TA,Picci P,Capanna R,Bernini G,Muller C,Tienghi A, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 884552.
  • 18
    Smeland S,Muller C,Alvegard TA,Wiklund T,Wiebe T,Bjork O,Stenwig AE,Willen H,Holmstrom T,Folleras G,Brosjo O,Kivioja A, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 48894.
  • 19
    Craft A,Cotterill S,Malcolm A,Spooner D,Grimer R,Souhami R,Imeson J,Lewis I. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998; 16: 362833.
  • 20
    Bonadonna G,Valagussa P,Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 73946.
  • 21
    Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516.
  • 22
    Juergens C,Weston C,Lewis I,Whelan J,Paulussen M,Oberlin O,Michon J,Zoubek A,Juergens H,Craft A. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47: 229.
  • 23
    Klimm B,Reineke T,Haverkamp H,Behringer K,Eich HT,Josting A,Pfistner B,Diehl V,Engert A. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 2005; 23: 800311.
  • 24
    Gusella M,Crepaldi G,Barile C,Bononi A,Menon D,Toso S,Scapoli D,Stievano L,Ferrazzi E,Grigoletto F,Ferrari M,Padrini R. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol 2006; 17: 165660.
  • 25
    Kaminski A,Joseph D,Elsaleh H. Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. Australas Radiol 2007; 51: 2838.
  • 26
    Ramani VS,Gollins SW,Wong H. Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. Clin Oncol (R Coll Radiol) 2006; 18: 64957.
  • 27
    Bacci G,Longhi A,Ferrari S,Mercuri M,Versari M,Bertoni F. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006; 45: 46975.
  • 28
    Gehan EA,Nesbit ME,Jr,Burgert EO,Jr,Viettit J,Tefft M,Perez CA,Kissane J,Hempel C. Prognostic factors in children with Ewing's sarcoma. Natl Cancer Inst Monogr 1981: 2738.
  • 29
    Bielack SS,Kempf-Bielack B,Delling G,Exner GU,Flege S,Helmke K,Kotz R,Salzer-Kuntschik M,Werner M,Winkelmann W,Zoubek A,Jurgens H, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 77690.
  • 30
    Dobbs NA,Twelves CJ,Gillies H,James CA,Harper PG,Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995; 36: 4736.
  • 31
    Hempel G,Flege S,Wurthwein G,Boos J. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2002; 49: 13341.
  • 32
    Lee YT,Chan KK,Harris PA,Cohen JL. Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer 1980; 45: 22319.
  • 33
    Morgan DJ,Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994; 26: 292307.
  • 34
    Rodvold KA,Rushing DA,Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 13217.
  • 35
    Burgert EO,Jr,Nesbit ME,Garnsey LA,Gehan EA,Herrmann J,Vietti TJ,Cangir A,Tefft M,Evans R,Thomas P. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8: 151424.
  • 36
    Bacci G,Longhi A,Versari M,Mercuri M,Briccoli A,Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 115461.
  • 37
    Meyers PA,Schwartz CL,Krailo M,Kleinerman ES,Betcher D,Bernstein ML,Conrad E,Ferguson W,Gebhardt M,Goorin AM,Harris MB,Healey J, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 200411.
  • 38
    Mankin HJ,Hornicek FJ,Rosenberg AE,Harmon DC,Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004; 429: 28691.
  • 39
    Souhami RL,Craft AW,Van der Eijken JW,Nooij M,Spooner D,Bramwell VH,Wierzbicki R,Malcolm AJ,Kirkpatrick A,Uscinska BM,Van Glabbeke M,Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 9117.
  • 40
    Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590611.
  • 41
    Rousseau A,Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16: 25362.
  • 42
    Rousseau A,Marquet P,Debord J,Sabot C,Lachatre G. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000; 38: 31553.
  • 43
    Evans WE,Relling MV,Rodman JH,Crom WR,Boyett JM,Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499505.